Association between CYP2E1 polymorphisms and susceptibility to prostate cancer

Eur J Cancer Prev. 2003 Jun;12(3):205-11. doi: 10.1097/00008469-200306000-00007.


Several genetic alterations have been associated with sporadic prostate cancer (PCa). In this study, the association between RsaI and DraI polymorphisms of CYP2E1 and PCa risk was analysed in a case-control study of 227 individuals using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Regarding DraI polymorphisms, the DD genotype is over-represented in PCa cases when compared with the control group (odds ratio (OR) 2.12; 95% confidence interval (CI) 1.11-4.05; P=0.022). Regarding the RsaI polymorphism, no significant differences were found. The results of this study indicate that DraI polymorphisms of the CYP2E1 gene may be associated with a twofold increased risk for the development of PCa.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Biomarkers, Tumor / blood
  • Case-Control Studies
  • Continental Population Groups / genetics
  • Cytochrome P-450 CYP2E1 / genetics*
  • Gene Frequency / genetics
  • Genetic Markers / genetics
  • Genetic Predisposition to Disease / epidemiology
  • Genetic Predisposition to Disease / genetics*
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length*
  • Portugal / epidemiology
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / metabolism
  • Risk Factors
  • Statistics as Topic


  • Biomarkers, Tumor
  • Genetic Markers
  • Cytochrome P-450 CYP2E1
  • Prostate-Specific Antigen